Video Experimental Relacionado
Updated: Jul 29, 2026
07:26
High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
El locus de susceptibilidad para la enfermedad de Alzheimer en el cromosoma 10
A Myers1, P Holmans, H Marshall
1Department of Psychiatry, Washington University School of Medicine, 660 S. Euclid, St. Louis, MO 63110, USA.
Science (New York, N.Y.)
|December 23, 2000
Resumen
Los investigadores identificaron un nuevo gen de riesgo de la enfermedad de Alzheimer en el cromosoma 10. Este hallazgo es significativo ya que sugiere que otros factores genéticos contribuyen a la enfermedad de Alzheimer de aparición tardía más allá del gen APOE.
Área de la Ciencia:
- Genética La genética.
- La neurociencia es la neurociencia.
- Investigación médica Investigación médica.
Sus antecedentes:
- El gen de la apolipoproteína E (APOE), específicamente el alelo APOE4, es el principal factor de riesgo genético conocido para la enfermedad de Alzheimer de inicio tardío (LOAD).
- Una proporción significativa de los casos de LOAD (50%) no son portadores del alelo APOE4, lo que indica la existencia de otros factores de susceptibilidad genética.
- La identificación de estos factores adicionales es crucial para una comprensión completa de la patogénesis de la LOAD.
Objetivo del estudio:
- Para llevar a cabo una pantalla de todo el genoma en pares de hermanos afectados por LOAD para identificar nuevos loci de susceptibilidad.
- Investigar los factores de riesgo genéticos para la enfermedad de Alzheimer más allá del gen APOE establecido.
- Para proporcionar evidencia de un nuevo locus de la enfermedad de Alzheimer en el cromosoma 10.
Principales métodos:
- Se realizó una pantalla de todo el genoma en dos etapas utilizando parejas de hermanos diagnosticados con LOAD.
- Se utilizó el análisis del logaritmo multipunto de la puntuación de probabilidades (LOD) para evaluar la vinculación.
- Se analizaron marcadores genéticos, incluido D10S1225, para identificar con precisión los posibles lugares de susceptibilidad.
Principales resultados:
- El estudio detectó evidencia significativa de un locus de susceptibilidad a la enfermedad de Alzheimer en el cromosoma 10.
- La puntuación LOD multipunto aumentó de 2,48 en la etapa uno (266 parejas de hermanos) a 3,83 en la etapa dos (429 parejas de hermanos) cerca de D10S1225.
- Este locus identificado demuestra un efecto independiente en el riesgo de enfermedad de Alzheimer, independientemente del genotipo APOE.
Conclusiones:
- Se ha identificado un nuevo locus de susceptibilidad a la enfermedad de Alzheimer en el cromosoma 10.
- Este locus contribuye al riesgo de LOAD independientemente del genotipo APOE.
- El descubrimiento pone de relieve la compleja arquitectura genética de la enfermedad de Alzheimer y abre caminos para una mayor investigación de los factores de riesgo genéticos no-APOE.
Videos de Conceptos Relacionados
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...